Certified Hyperbaric Technologist Practice Test

What is a significant risk associated with the use of Cis-Platinum in animal studies?

1. Increased pulmonary fibrosis

2. Decreased wound breaking strength

3. Increased cardiac toxicity

4. Neuropathy

The correct answer is: Decreased wound breaking strength

Cis-Platinum, also known as Cisplatin, is a chemotherapy drug used primarily to treat various forms of cancer. In animal studies, one of the significant risks linked to its use is decreased wound breaking strength. This side effect is particularly relevant in contexts where healing is crucial, such as surgical recovery or in patients with open wounds. Decreased wound breaking strength indicates that the tissue's integrity and ability to withstand forces are compromised, potentially leading to complications in wound healing. Cisplatin can affect collagen synthesis and overall tissue regeneration, thereby weakening the structural properties of wounds. While other risks associated with Cisplatin usage, such as pulmonary fibrosis, cardiac toxicity, and neuropathy, are important considerations in clinical settings, the impact on wound healing and wound integrity is increasingly notable, especially in studies examining recovery post-surgery or trauma. Thus, acknowledging the implications of decreased wound breaking strength is critical for understanding the broader effects of Cisplatin in both animal studies and potential therapeutic applications.